An appraisal committee for the UK’s National Institute for Health and Care Evidence (NICE) has recommended against National Health Service (NHS) use of Lynparza (olaparib), AstraZeneca’s blockbuster cancer drug, for treating men with previously treated hormone-resistant metastatic prostate cancer with BRCA1 or BRCA2 mutations.
Source: Drug Industry Daily